Positive Effects of CRISPR-Cas9 Gene Editing for Dyslipidemia Endure Through 1 Year
A small first-in-human study reported sustained lipid reductions at one-year follow-up.
TL;DR
- Cleveland Clinic reported one-year follow-up results for the CTX310 gene-editing study in dyslipidemia.
- The study was an early-phase trial, and the collected report describes a small participant group.
- The findings are preliminary and do not establish long-term safety or clinical benefit.
Cleveland Clinic reported that CTX310, a CRISPR-Cas9 approach targeting ANGPTL3, showed effects through one year in a first-in-human Phase 1a trial. ScienceDaily separately reported the one-year follow-up and described the study as a single-treatment trial. [1] [2]
These are early clinical findings from a small study. The sources do not establish durable outcomes beyond the reported follow-up or support any treatment recommendation. [1] [2]
Why it matters
A one-time gene-editing approach would represent a different development model from repeated lipid-lowering medicines, but the evidence here remains at an early clinical stage. The next signal is whether later trials confirm safety and durability.
Editor's note
Headline is verbatim from Cleveland Clinic's report of the study. Limited to reported trial-stage findings; no medical advice or efficacy extrapolation.